A 58-year-old postmenopausal woman presents to the gynecology clinic with a 3-month history of irregular vaginal bleeding. Which assessment finding would be most significant in evaluating for endometrial cancer?

Postmenopausal bleeding is the most significant symptom of endometrial cancer, occurring in about 90% of cases. Other symptoms like pelvic pain or urinary issues are less specific and not classic presentations.

Clinical Presentation & Significance
A 58-year-old postmenopausal woman with a 3-month history of irregular vaginal bleeding presents a classic clinical scenario. The most significant assessment finding for evaluating endometrial cancer in this context is postmenopausal bleeding (PMB). While the patient’s chief complaint is irregular bleeding, recognizing this symptom specifically as PMB—any vaginal bleeding occurring after 12 months of amenorrhea—is the critical first step in risk stratification. Updated clinical guidance emphasizes that PMB is the cardinal presenting symptom of endometrial cancer, and the primary role of initial assessment is to triage these patients for further diagnostic evaluation ^[2].

Pathophysiology & Clinical Reasoning
Endometrial cancer arises from the glandular tissue of the uterine lining, often driven by unopposed estrogen stimulation, which leads to endometrial proliferation, hyperplasia, and eventually malignant transformation. As the neoplastic tissue outgrows its blood supply or invades local vasculature, it becomes friable and prone to spontaneous, irregular shedding, which manifests clinically as postmenopausal bleeding. This symptom is the most common and earliest indicator of endometrial malignancy, reported in over 90% of cases . The other listed symptoms—pelvic pain, weight loss, fatigue, and urinary frequency—are more indicative of advanced or metastatic disease, where the tumor mass exerts pressure on adjacent pelvic structures or systemic effects of malignancy occur. Therefore, in the initial evaluation, the presence of PMB itself is the most significant finding that directly prompts the diagnostic pathway, which historically relied on transvaginal ultrasound (TVUS) to measure endometrial thickness (ET) ^[2].

Diagnostic Nuance & Evidence Update
A crucial nuance for NCLEX-RN preparation is understanding the limitations of the traditional triage tool. While an endometrial thickness of ≤4 mm on TVUS was previously considered sufficient to exclude cancer with high sensitivity, recent evidence has challenged this. A retrospective cohort study found that certain aggressive subtypes, particularly non-endometrioid histologies like serous carcinoma, can present with a thin endometrial stripe, even when controlling for cases with incomplete visualization ^[1]. This means a thin endometrium on ultrasound does not reliably rule out malignancy in all patients. Consequently, updated ACOG guidance now recommends a combined approach of TVUS and endometrial sampling for the evaluation of most patients with PMB, moving away from using ultrasound alone as a definitive triage tool ^[2]. This shift is reinforced by research showing the low specificity of TVUS, which leads to many invasive follow-up procedures, and its potential to miss up to a quarter of high-risk serous cancers . The definitive diagnosis of endometrial cancer is made through histopathological evaluation of an endometrial tissue sample obtained via biopsy, dilation and curettage, or hysterectomy .